Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

Simone Boehrer; Lionel Adès; Thorsten Braun; Lorenzo Galluzzi; J. Grosjean; Claire Fabre; Geneviève Roux; Claude Gardin; Antoine Martin; Stéphane de Botton; Pierre Fenaux; Guido Guido Kroemer

doi:10.1182/blood-2007-07-100362

Related publications

Article2007

P039 The EGFR-inhibitor erlotinib exhibits various off-target effects in MDS and AML

Simone Boehrer, L. Adàs, Theodore P. Braun, Lorenzo Galluzzi, Joël Grosjean, Claire Fabre, Stéphane de Botton, Claude Gardin, Pierre Fenaux, Guido Guido Kroemer

Article2011

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Élodie Lainey, Marie Sébert, Cyrielle Bouteloup, Carole Leroy, Sylvain Thépot, Maximilien Tailler, Lionel Adès, Claude Gardin, Guido Guido Kroemer, Pierre Fenaux, Simone Boehrer

Article2007

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Simone Boehrer, Lionel Adès, Thorsten Braun, Lorenzo Galluzzi, J. Grosjean, Claire Fabre, Geneviève Roux, Claude Gardin, Antoine Martin, Stéphane de Botton, Pierre Fenaux, Guido Guido Kroemer

Article2016

Immunological off-target effects of imatinib

Laurence Zitvogel, Sylvie Rusakiewicz, Bertrand Routy, Maha Ayyoub, Guido Guido Kroemer

Article2010

Erlotinib Inhibits ABC Transporters of AML Progenitors with Stem Cell Features and Increases Chemosensitivity to Current AML Drugs

Marie Sébert, Élodie Lainey, Sylvain Thépot, Maximilien Tailler, Lionel Adès, Claude Gardin, Pierre Fenaux, Guido Guido Kroemer, Simone Boehrer